Figures & data
Figure 1 (A) Registries used to combine administrative, clinical, and outcome data. (B) Flowchart showing the selection of the study population.
![Figure 1 (A) Registries used to combine administrative, clinical, and outcome data. (B) Flowchart showing the selection of the study population.](/cms/asset/1a39cc4a-8945-4bcd-bf46-ee1f40de7ff1/dcle_a_12163144_f0001_b.jpg)
Table 1 Patient characteristics according to distance to nearest specialized treatment center in 2,992 adult AML patients
Table 2 Association between distances to nearest specialized treatment center and probability of intensive chemotherapy in 2,992 acute myeloid leukemia patients. Logistic regression analysis, crude, and adjusted estimatesa
Figure 2 Association between distances to the nearest specialized treatment center and mortality. Results of all AML patients by age and by treatment intensity. Cox regression analysis, crude, and adjusted estimates.a
Abbreviations: AML, acute myeloid leukemia; 95% CI, 95% confidence interval.
![Figure 2 Association between distances to the nearest specialized treatment center and mortality. Results of all AML patients by age and by treatment intensity. Cox regression analysis, crude, and adjusted estimates.a](/cms/asset/423935d1-f069-4114-8ff7-fd5f95e686fc/dcle_a_12163144_f0002_b.jpg)
Table 3 Association between distances to nearest specialized treatment center and probability of CR in 1,463 AML patients treated with remission-induction therapy. Logistic regression analysis, crude, and adjusted estimatesa
Figure 3 Crude survival according to categorical distance to the nearest specialized treatment center. Overall survival in all patients (A), in patients <65 years (B), in all patients ≥65 years (C), in all patients receiving intensive chemotherapy (D), and in all patients receiving intensive chemotherapy surviving to achieve a CR (E).
![Figure 3 Crude survival according to categorical distance to the nearest specialized treatment center. Overall survival in all patients (A), in patients <65 years (B), in all patients ≥65 years (C), in all patients receiving intensive chemotherapy (D), and in all patients receiving intensive chemotherapy surviving to achieve a CR (E).](/cms/asset/beb02790-3aae-4db8-9f7a-e783ed540287/dcle_a_12163144_f0003_c.jpg)